TSE:HLS HLS Therapeutics Q3 2024 Earnings Report C$4.23 +0.06 (+1.44%) As of 04/25/2025 03:45 PM Eastern Earnings HistoryForecast HLS Therapeutics EPS ResultsActual EPS-C$0.20Consensus EPS -C$0.19Beat/MissMissed by -C$0.01One Year Ago EPS-C$0.28HLS Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AHLS Therapeutics Announcement DetailsQuarterQ3 2024Date11/7/2024TimeBefore Market OpensConference Call DateThursday, November 7, 2024Conference Call Time8:30AM ETConference Call ResourcesConference Call AudioConference Call TranscriptInterim ReportEarnings HistoryCompany ProfilePowered by HLS Therapeutics Q3 2024 Earnings Call TranscriptProvided by QuartrNovember 7, 2024 ShareLink copied to clipboard.There are 5 speakers on the call. Operator00:00:00Good morning, and welcome to the Q3 Fiscal 20 24 Financial Results Conference Call for HLS Therapeutics. At this point, I would like to turn the call over to David Mason, Investor Relations, for the introductory remarks. Speaker 100:00:16Good morning, everyone, and thank you for joining us today. With me in the room on the call, we have Craig Millian, Chief Executive Officer John Hanna, Chief Financial Officer and Brian Walsh, Chief Commercial Officer. Earlier this morning, we issued a news release announcing our financial results for the 3 9 months ended September 30, 2024. This news release, along with our MD and A and financial statements, is available on our website and on SEDAR Plus. Please note that slides accompanying today's call can be viewed via the live webcast, a link to which is available in our earnings press release and at our website on the Events page. Speaker 100:01:06Certain matters discussed in today's conference call or answers that may be given to questions could constitute forward looking statements. Actual results could differ materially from those anticipated. Risk factors that could affect results are detailed in our annual information form, which has been filed on SEDAR Plus at www.sedarplus. Ca. During the call, we will refer to adjusted EBITDA. Speaker 100:01:37Adjusted EBITDA does not have any standardized meaning prescribed by IFRS. Adjusted EBITDA is defined in our press release and annual filings that are available on SEDAR Plus and on our website. Please note that all financial information provided is in U. S. Dollars unless otherwise specified. Speaker 100:02:00I would now like to turn the meeting over to Mr. Millian. Please go ahead. Speaker 200:02:04Thanks, Dave. Good morning, everyone, and thank you for joining us. On our call today, I'll review Q3 highlights. John will follow with a more detailed look at our financial results, then we'll hold a Q and A session. Also joining us for today's Q and A is Brian Walsh, our Chief Commercial Officer. Speaker 200:02:23Financial results for the Q3 included revenue of $14,100,000 adjusted EBITDA of $4,100,000 and cash from operations of $1,500,000 Q3 saw the continued growth of our promoted products in Canada, driven by the strongest quarterly growth of the year for Vascepa. Our net sales in Canada grew 9% in Q3 over the prior year and that's 11% growth in constant currency. Vascepa's year over year net sales increased 28% or 30% in constant currency and were up 13% over the 2nd quarter. At the same time, we further reduced our Q3 operating expenses by 15% over prior year, excluding cost of goods. And we made a significant debt repayment to strengthen our balance sheet as we work towards increasing future cash flow and financial flexibility. Speaker 200:03:24Since the start of the year, we've grown product sales while reducing operating expenses by 10%. We've also lowered debt on our balance sheet by more than $18,000,000 This puts us in a much stronger financial and operating position entering 2025 than where we started the year. Illustrating the health of our core business, if we take out royalty revenue and consider adjusted EBITDA based solely on product sales and related expenses, Q3 adjusted EBITDA would have grown 55% year over year. This is relevant in that royalty revenues will become a much smaller part of the baseline when calculating growth in future quarters. Now before moving on to Q3 brand performance, I wanted to provide a brief update regarding my leadership team. Speaker 200:04:16I'm pleased to formally announce that we have removed the interim tag from his title and John Hanna has been appointed as our permanent Chief Financial Officer. In addition, Brian Walsh, who joined HLS last summer as our Head of Commercial, has been promoted to Chief Commercial Officer. Both John and Brian have been instrumental over the past year in helping to drive significant changes at HLS, strengthening both our operating performance and financial foundation. I believe we are building the right leadership team and organizational capabilities to both optimize our current performance as well as further scale our business in the future. Now moving on to brand performance. Speaker 200:05:01I'll start my Q3 review with a look at Vascepa, which had its strongest sales growth quarter of the year with net revenue up 30% in constant currency. Our brand objectives have been to drive demand, reduce expenses and stabilize the public private payer mix. As a result of our efforts, the Q3 loss for Vascepa was $600,000 a considerable improvement from the $1,600,000 loss in Q2 and the smallest quarterly product related loss since launch. As I've mentioned on previous calls, we expect Vascepa to make a positive brand contribution to adjusted EBITDA starting in Q4 of this year. Importantly, cost savings have not come at the expense of growth. Speaker 200:05:52Vascepa unit demand grew 45% in Q3 and along with consistent prescriber growth of 66% reflects the ongoing health of the brand. In Q3, we took important steps to finish the year strong and to drive profitable growth for Vascepa in 2025 and beyond. One significant change was to bring primary care sales activities in house from Pfizer. This transition went smoothly and was completed by the end of August. We maintained our growth rate throughout Q3, even while working through the handoff process, which speaks to the efforts and professionalism of both the HLS and Pfizer teams. Speaker 200:06:38Our new model is built for both efficiency and effectiveness. We are focused on 3 key elements to drive profitable growth. 1, a renewed emphasis on driving new patient starts 2, an increased focus on physician practices with a high number of privately insured patients and 3, providing reimbursement and patient support programs to augment our selling efforts. With our new model, we're covering over 80% of all Vascepa prescribers as well as over 90% of prescribers who have initiated 1 or more new patients within the last 12 months. Despite a considerable reduction in total sales force size, this model still provides coverage of active Vascepa prescribers that's comparable to what we had previously with Pfizer. Speaker 200:07:32Approximately 2 thirds of our sales force effort will be focused on existing prescribers. Here, we want to increase prescribing depth amongst those physicians who are initiating new to brand patient starts. The other one third of selling activity is allocated to targeting those high potential writers who have yet to prescribe. We estimate that bringing primary care in house will result in annual net savings of about $4,000,000 Importantly, we don't believe these savings will come at the expense of growing Vascepa further. We're confident in our new selling model for 5 key reasons. Speaker 200:08:11Number 1 is coverage. We still maintain high level of coverage with existing prescribers and high potential non writers. Number 2 is targeting. We are incorporating new data sources to improve the return on investment of our selling efforts. One example includes leveraging a new data set that captures payer dynamics at the practice level. Speaker 200:08:32This has enabled us to increase focus on the private payer opportunity where most plans have broader patient eligibility criteria, a simpler reimbursement process and a higher value per script. Number 3 is focus. Brand awareness is high in primary care due to Pfizer's previous activities. That said, Vascepa is our only focus on each sales call, whereas the Pfizer primary care reps were responsible for detailing multiple products across different therapeutic areas. Number 4 is ownership. Speaker 200:09:07We are observing synergies in having our reps as a single point of customer contact within a given geography. For example, making connections between specialists and general practitioners that previously would require coordination between the HLS and Pfizer teams can now be handled by a single sales professional. And finally, number 5 is flexibility. Our ability to pivot more quickly on messaging, targeting and other sales tactics is now enhanced. A recent example is an increased focus on the significant cardiovascular death benefit from REDUCE IT, which is a highly differentiating clinical message for Vascepa. Speaker 200:09:47Beyond these important changes to our selling model, we also continue to make progress on reimbursement and patient retention. We gained public access in Alberta in August, which brings our national coverage to more than 90% of Canadian lives covered by public payer plans. It's still early days in Alberta, but we are encouraged by the progress so far, particularly as it relates to recent growth in new patient starts. In Ontario and Quebec, our dedicated field nurses continue to be a resource to physician offices in helping manage the reimbursement process. In offices that utilize these resources, we see higher approval rates and reduced waiting times for new patients. Speaker 200:10:34To improve patient retention, we enhanced our co pay program in May with a particular focus on privately insured patients who are more likely to drop off therapy due to higher co pays. While it is still in the early days of the program, initial results are encouraging in demonstrating a higher level of retention. Improving the retention rate for privately insured patients should also help stabilize the payer mix. So to sum up on Vascepa, we are excited to regain full responsibility for all sales activities. The sales force transition went smoothly, and we have continued to see unit volumes steadily grow in September October. Speaker 200:11:15And we expect Vascepa to deliver a positive brand contribution to adjusted EBITDA for the first time starting in Q4. As a reminder, Vascepa has a long patent runway into the late 2030s, and as such, we believe it will be a profitable growth driver for HLS for many years. Looking now at Clozaril. Our Canadian business continues to deliver encouraging results with Q3 up about 1% year over year in constant currency, while year to date revenue is essentially flat. With a positive start to Q4, we remain on track to stabilize or even modestly grow the Canadian Clozril business this year, driven by our regional strategies in Ontario, Quebec and Western Canada. Speaker 200:12:06In Quebec, Bill 92 limits the ability of prescribers to start new patients on branded Clozaril. Therefore, we recently shifted from a traditional selling approach that focuses on new patient acquisition to a model focused retaining current Clozaril patients. We believe this new approach is working. Since adopting our new model earlier this year in Quebec, Clozaril has seen the lowest decline in net patients in that province since Bill 92 came into effect. In Western Canada, we continue to drive market share expansion and in Ontario, we are leveraging HLS's strong leadership position. Speaker 200:12:47As a result, our performance throughout Canada has more than offset small losses in Quebec. Q3 Clozaril patient growth in Canada was 1.8%, while unit volumes were up about 1% versus prior year. This was driven by patient growth of more than 15% in British Columbia and 3% in Ontario, offsetting patient decline of about 3% in Quebec. Now in contrast to our Canadian Clozaril business, which is flat to last year, the U. S. Speaker 200:13:21Performance is behind plan and we expect U. S. Clozaril net sales will decline about $1,000,000 versus last year. As I've spoken about on previous calls, underlying demand is relatively stable and the sales decline is mainly due to high wholesaler inventory levels at the end of last year. We expected this inventory overhang could be offset through incremental gains in new business as well as through a modest price increase that was taken mid year. Speaker 200:13:51We have made improvements to our existing specialty pharmacy program to help drive business, but an additional goal of expanding our U. S. Pharmacy network will likely happen in 2025 rather than this year. Now moving on to our balance sheet and future capital allocation. While we take steps to grow our product portfolio and improve profitability, we're also strengthening our balance sheet. Speaker 200:14:18During the Q3, we made a significant debt repayment of $14,000,000 using the upfront cash proceeds received from the sale of our ZEMPOZYM royalty interest. This, along with our regular quarterly principal repayment, has lowered our net debt position to $52,400,000 We plan to continue to delever and further strengthen our financial position. We also expect to resume share buybacks in early 2025 as well as more aggressively pursue BD opportunities to expand our product portfolio. As it's a question that often comes up, I'd like to touch briefly development. HLS is highly regarded within Canada for our capabilities and customer relationships within specialty therapeutic areas. Speaker 200:15:08And this positions us well as a potential Canadian licensing partner. As such, we are interested in pursuing assets that are potentially synergistic with our current portfolio and accretive in the near term. Our current BD targeting approach is based on 4 criteria. 1, identify commercial stage assets that are available to license in Canada 2, that are within our therapeutic areas of focus 3, that we believe have considerable sales potential and 4, that won't require significant upfront capital or a large increase in OpEx. In summary, our intent is to bring in assets at a reasonable cost that could significantly grow the top line, while also allowing us to more fully leverage the infrastructure, expertise and capabilities we have built in Canadian specialty markets, specifically within cardiovascular and CNS. Speaker 200:16:04Now that we've made considerable progress in addressing our cost structure and strengthening our balance sheet, adding to the portfolio will be an important lever to accelerate both top line and bottom line growth beyond 2025. Moving on to 2024 full year guidance. We are now guiding to a revenue range of $56,500,000 to $57,200,000 lowered from the previous range of $58,500,000 to $59,700,000 The revised guidance is attributable to year to date U. S. Clozaril sales being behind plan and from the negative foreign exchange impact on the company's Canadian business due to the persistent strength of the U. Speaker 200:16:50S. Dollar relative to the Canadian dollar in 2024. As I stated before, the underlying demand fundamentals for U. S. Clozaril remain sound and the net sales decline is due to what we believe are transient issues. Speaker 200:17:06Sales performance for our Canadian business for both Vascepa and Clozaril is in line with expectations, but reporting results are impacted by the translation to U. S. Dollars. Based on the positive progress in reducing operating costs, we are raising the low end of our 2024 adjusted EBITDA guidance to $16,000,000 to $16,700,000 compared to the previous range of 15.5 $1,000,000 to $16,700,000 We are also reaffirming that Vascepa will make a positive brand contribution to adjusted EBITDA starting in Q4. With our release today, we are also providing a preliminary outlook for next year. Speaker 200:17:50In 2025, we expect that revenue growth from our promoted product portfolio will be in the high single digit percentage range, while growth in consolidated adjusted EBITDA will be in the mid-20s percentage range. We will update our 2025 financial outlook when we release our 2024 year end results in March next year. In closing, we are executing our plan and have made necessary changes throughout this transition year to significantly reduce OpEx and debt levels. We believe this sets up well for 2025 with 2 profitable products generating top line growth along with a stronger balance sheet than we entered 2024 with. This should allow us to resume stock buybacks early next year and pursue portfolio expansion opportunities. Speaker 200:18:40With that, I'll turn it over to John for a closer look at the numbers. John? Speaker 300:18:45Thank you, Craig, and good morning, everyone. Starting with revenue, total revenue for Q3 was $14,100,000 compared to $16,000,000 in Q3 last year. Excluding royalties, revenue from marketed products in Q3 was $13,900,000 up 3% from Q3 2023. Canadian product sales of Vascepa and Plazril in Q3 were up 11% in Canadian dollars. Q3 sales growth in Canada was driven by Vascepa with revenue up 30% in Canadian dollars. Speaker 300:19:21The variance between unit demand growth and net sales growth through Vascepa is due to trends in gross to net pricing. As public access ramps in BC and Alberta following the listings there this year, we expect near term divergence between unit growth and net sales. However, longer term, we expect this to stabilize as public payer growth normalizes. And as Craig discussed, we are also pursuing initiatives to drive patient pardon me, drive private payer patient adoption. U. Speaker 300:19:51S. Closure product sales were down 15% in Q3 and 8% for the year to date period. As Craig touched on, year to date results have been impacted by wholesaler purchasing patterns, including a high level of wholesaler inventory at the start of the year as well as a key downstream customer switching from 1 wholesaler to another, a transition that took place during Q3. The result of this change was lower days on hand of inventory at wholesalers at September 30. This appears to have rebalanced in October. Speaker 300:20:27Royalty revenues were $200,000 in Q3, down from $2,600,000 in Q3 last year. As you know, the royalty term for Emblem, what was the largest royalty in the portfolio came to an end in Q4 last year. In addition, we sold our royalty interest in Zempozyme at the end of Q2 this year. So while prior period royalty includes royalty revenue contributions from multiple royalty interests, Q3 2024 royalty revenue did not include either Emblem or Zempozyme. As Craig mentioned, following the sale of Zempozyme, we used the cash proceeds to make a $14,000,000 principal payment on our term loan in Q3, which will save us approximately $1,500,000 in annual interest expense. Speaker 300:21:17On the expense side, we continued to make progress in Q3 with reducing our cost base while maintaining the growth potential of the business. Q3 operating expenses comprising sales and marketing, G and A and medical regulatory and patient support were down 15%, while promoted product revenue in Canada was up 9%. With the transition of the primary care sales function to HLS completed at the end of August, we generated some related savings in Q3, but we'll see a more substantive decrease in sales and marketing expense in Q4 this year, which will continue going forward. As Craig said earlier, we expect the transition to save us a net amount of approximately $4,000,000 annually or about $1,000,000 per quarter starting in Q4. We recorded other costs in the quarter of approximately $600,000 related to the exiting of the co promotional agreement. Speaker 300:22:15In Q4, we expect another related expense though of a smaller magnitude. Finally, cost of product sales increased in Q3 due to growth of Vascepa year over year. Q3 adjusted EBITDA was $4,100,000 compared to $5,100,000 in Q3 2023. Excluding royalty revenue, adjusted EBITDA for Q3 would have been $3,900,000 compared to $2,500,000 in Q3 last year. This represents a year over year increase of 55%. Speaker 300:22:50This reflects the growth in our promoted product revenue as well as steps we have taken to reduce our cost base. For Q3, the Direct Brand contribution from Clozaril to adjusted EBITDA was $6,800,000 while the Direct Brand contribution from Vascepa to adjusted EBITDA was a loss of 600,000 dollars Year to date, the Direct Brand contribution from Clozaril to adjusted EBITDA was $20,500,000 while the Direct Brand contribution from Vascepa to adjusted EBITDA was a loss of 3,800,000 dollars By comparison for the same year to date period 2023, Vascepa brand contribution was negative $6,900,000 We've seen a 45% improvement. Cash from operations in Q3 was $1,500,000 compared to $5,400,000 in Q3 last year. Cash and cash equivalents were $17,500,000 at quarter end compared to $22,000,000 at December 31, 2023. We continue to delever our balance sheet and made a regular principal repayment on our term loan during Q3 of approximately $1,000,000 in addition to the $14,000,000 debt repayment mentioned earlier. Speaker 300:24:06At the quarter end, the principal balance on the term loan stood at $70,000,000 down significantly from $88,500,000 at the end of 2023. Our net debt at the end of Q3 stood at $52,400,000 dollars In closing, I'm excited to take on the role of permanent CFO this time in the company's evolution. We expect to end the year with a stronger balance sheet, reduced cost base and an outlook for 2 profitable products in 2025. Overall, the improvements we've made in 2024 put us in a financial position to support the potential of our existing products, while providing the optionality to buy back shares and our expand product portfolio. And with that, I'll pass it back to Craig for his closing comments. Speaker 200:24:54Thanks, John. To sum up, we are making progress in executing our plan, continuing to grow our promoted products while significantly reducing operating expenses and paying down debt in 2024. We believe the changes we're making this year will set HLS up for top line growth and increased profitability in 2025 and create greater flexibility for capital allocation in the future. That concludes my prepared remarks. At this point, I'll ask the operator to please provide instructions for asking a question. Speaker 200:25:26Operator? Operator00:25:28Thank you. And ladies and gentlemen, we will now begin the question and answer And your first question comes from the line of George Olyvishov with Klarman Securities. Please go ahead. Speaker 300:26:39Good morning, guys. Thanks for taking our questions and congrats, John, on the appointment. Just a few here on my end. Can you guys talk a little bit about the trends you're seeing when it comes to relative growth in consistent prescribers for Vascepa in each of the 4 key provinces? Speaker 200:27:00Thanks, George, for the question. And since we're also fortunate to have Brian Walsh here with us, our Chief Commercial Officer, maybe I'll see if Brian has some perspectives on the growth in consistent prescribers. And maybe just to start, maybe a definition of what that is, Brian? Speaker 400:27:24Sure. Thanks George. Thanks for the question. Thanks Craig. So consistent prescribers, we look at nationally. Speaker 400:27:34It's defined by prescribers that have written 4 out of the last 5 weeks. We've seen 66% growth versus last year in consistent prescribers. And now approximately 45% of our prescribers within the quarter were consistent prescribers for Vascepa. Yes. Do we Speaker 200:27:53see any differences in terms of regional differences? I think that and I'm not sure if we have that information handy, so we might need to follow-up with you on that, George. Speaker 400:28:01I think the one metric we look at it very closely regionally is more new to brand initiators. So for the quarter, we saw the biggest improvement there in BC as expected with access about 75% increase in new to brand writers in BC for Q3 versus Q3 prior year. Speaker 300:28:22Got it, got it. Understood. Thanks, Brian, and thanks, Greg. Moving on, I guess, also on Vascepa, can you give us a sense of roughly what percentage of new to brand patients today are originating from primary care versus specialty care? Speaker 400:28:40Yes. So it's about 2 thirds from specialty and 1 third from primary care in the most recent quarter. Speaker 300:28:51Okay. Got it. Got it. And just switching gears here a little bit. With respect to the expansion of the specialty pharmacy program for Clozro in the U. Speaker 300:29:02S, what are your plans for that? And what kind of impact are you guys expecting in 2025? Speaker 400:29:11Yes. So the program that we have in place now is it's been with a strong partner that's focused on providing access to branded Clozaril obviously in the U. S. We've seen that program double in size this year versus last year, now representing about 10% of our units for the U. S. Speaker 400:29:32So we expect to be able to continue to grow that program. That program has broadly national reach, but we have some pockets, regional pockets of opportunity that we aim to fill in with other mental health specialty pharmacies in the U. S. In 2025. So I think we can expect to see that level of growth within the program, which is offsetting any decline in base business in the rest of the country. Speaker 300:30:00Understood. Understood. That's it for me. Thank you, guys. Thanks, George. Operator00:30:08Thank you. And there are no further questions at this time. I would like to turn it back to Craig Millian for closing remarks. Speaker 200:30:14Great. Thank you. And thanks for participating on today's call. And we look forward to continuing to report on our progress in the coming quarters and speaking with you all again soon. Goodbye. Speaker 200:30:25Have a great day. Operator00:30:28Thank you. Ladies and gentlemen, this concludes today's conference call. Thank you all for participating. You may now disconnect.Read morePowered by Conference Call Audio Live Call not available Earnings Conference CallHLS Therapeutics Q3 202400:00 / 00:00Speed:1x1.25x1.5x2x Earnings DocumentsInterim report HLS Therapeutics Earnings HeadlinesHLS Therapeutics Inc (HLS) Receives a Hold from Stifel NicolausMarch 14, 2025 | markets.businessinsider.comHLS Therapeutics Appoints Christine Elliott to its Board of DirectorsMarch 13, 2025 | finance.yahoo.comReal Americans Don’t Wait on Wall Street’s Next MoveWhat's happening in the markets right now should concern every freedom-loving American who's worked hard and saved smart. Your 401(k) doesn't deserve to be dragged through the mud by tariffs, trade wars, reckless spending, and political standoffs. And you don't have to stand by while Wall Street plays roulette with your future.April 27, 2025 | Premier Gold Co (Ad)HLS Therapeutics Gets Green Light for Share Buyback ProgramMarch 13, 2025 | marketwatch.comTop Canadian Pharmaceutical Stocks of 2025February 3, 2025 | fool.caOptimistic Buy Rating for HLS Therapeutics Despite Revenue ChallengesNovember 10, 2024 | markets.businessinsider.comSee More HLS Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like HLS Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on HLS Therapeutics and other key companies, straight to your email. Email Address About HLS TherapeuticsHLS Therapeutics (TSE:HLS) Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company is focused on treatment products for the central nervous system (CNS), and cardiovascular specialties. The company products include Clozaril, Absorica, Vascepa, CSAN Pronto, Trinomia and Perseris. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue. The company operates in Canada, the United States and the Rest of the world.View HLS Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Markets Think Robinhood Earnings Could Send the Stock UpIs the Floor in for Lam Research After Bullish Earnings?Market Anticipation Builds: Joby Stock Climbs Ahead of EarningsIs Intuitive Surgical a Buy After Volatile Reaction to Earnings?Seismic Shift at Intel: Massive Layoffs Precede Crucial EarningsRocket Lab Lands New Contract, Builds Momentum Ahead of EarningsAmazon's Earnings Could Fuel a Rapid Breakout Upcoming Earnings Cadence Design Systems (4/28/2025)Welltower (4/28/2025)Waste Management (4/28/2025)AstraZeneca (4/29/2025)Mondelez International (4/29/2025)PayPal (4/29/2025)Starbucks (4/29/2025)DoorDash (4/29/2025)Honeywell International (4/29/2025)Regeneron Pharmaceuticals (4/29/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
There are 5 speakers on the call. Operator00:00:00Good morning, and welcome to the Q3 Fiscal 20 24 Financial Results Conference Call for HLS Therapeutics. At this point, I would like to turn the call over to David Mason, Investor Relations, for the introductory remarks. Speaker 100:00:16Good morning, everyone, and thank you for joining us today. With me in the room on the call, we have Craig Millian, Chief Executive Officer John Hanna, Chief Financial Officer and Brian Walsh, Chief Commercial Officer. Earlier this morning, we issued a news release announcing our financial results for the 3 9 months ended September 30, 2024. This news release, along with our MD and A and financial statements, is available on our website and on SEDAR Plus. Please note that slides accompanying today's call can be viewed via the live webcast, a link to which is available in our earnings press release and at our website on the Events page. Speaker 100:01:06Certain matters discussed in today's conference call or answers that may be given to questions could constitute forward looking statements. Actual results could differ materially from those anticipated. Risk factors that could affect results are detailed in our annual information form, which has been filed on SEDAR Plus at www.sedarplus. Ca. During the call, we will refer to adjusted EBITDA. Speaker 100:01:37Adjusted EBITDA does not have any standardized meaning prescribed by IFRS. Adjusted EBITDA is defined in our press release and annual filings that are available on SEDAR Plus and on our website. Please note that all financial information provided is in U. S. Dollars unless otherwise specified. Speaker 100:02:00I would now like to turn the meeting over to Mr. Millian. Please go ahead. Speaker 200:02:04Thanks, Dave. Good morning, everyone, and thank you for joining us. On our call today, I'll review Q3 highlights. John will follow with a more detailed look at our financial results, then we'll hold a Q and A session. Also joining us for today's Q and A is Brian Walsh, our Chief Commercial Officer. Speaker 200:02:23Financial results for the Q3 included revenue of $14,100,000 adjusted EBITDA of $4,100,000 and cash from operations of $1,500,000 Q3 saw the continued growth of our promoted products in Canada, driven by the strongest quarterly growth of the year for Vascepa. Our net sales in Canada grew 9% in Q3 over the prior year and that's 11% growth in constant currency. Vascepa's year over year net sales increased 28% or 30% in constant currency and were up 13% over the 2nd quarter. At the same time, we further reduced our Q3 operating expenses by 15% over prior year, excluding cost of goods. And we made a significant debt repayment to strengthen our balance sheet as we work towards increasing future cash flow and financial flexibility. Speaker 200:03:24Since the start of the year, we've grown product sales while reducing operating expenses by 10%. We've also lowered debt on our balance sheet by more than $18,000,000 This puts us in a much stronger financial and operating position entering 2025 than where we started the year. Illustrating the health of our core business, if we take out royalty revenue and consider adjusted EBITDA based solely on product sales and related expenses, Q3 adjusted EBITDA would have grown 55% year over year. This is relevant in that royalty revenues will become a much smaller part of the baseline when calculating growth in future quarters. Now before moving on to Q3 brand performance, I wanted to provide a brief update regarding my leadership team. Speaker 200:04:16I'm pleased to formally announce that we have removed the interim tag from his title and John Hanna has been appointed as our permanent Chief Financial Officer. In addition, Brian Walsh, who joined HLS last summer as our Head of Commercial, has been promoted to Chief Commercial Officer. Both John and Brian have been instrumental over the past year in helping to drive significant changes at HLS, strengthening both our operating performance and financial foundation. I believe we are building the right leadership team and organizational capabilities to both optimize our current performance as well as further scale our business in the future. Now moving on to brand performance. Speaker 200:05:01I'll start my Q3 review with a look at Vascepa, which had its strongest sales growth quarter of the year with net revenue up 30% in constant currency. Our brand objectives have been to drive demand, reduce expenses and stabilize the public private payer mix. As a result of our efforts, the Q3 loss for Vascepa was $600,000 a considerable improvement from the $1,600,000 loss in Q2 and the smallest quarterly product related loss since launch. As I've mentioned on previous calls, we expect Vascepa to make a positive brand contribution to adjusted EBITDA starting in Q4 of this year. Importantly, cost savings have not come at the expense of growth. Speaker 200:05:52Vascepa unit demand grew 45% in Q3 and along with consistent prescriber growth of 66% reflects the ongoing health of the brand. In Q3, we took important steps to finish the year strong and to drive profitable growth for Vascepa in 2025 and beyond. One significant change was to bring primary care sales activities in house from Pfizer. This transition went smoothly and was completed by the end of August. We maintained our growth rate throughout Q3, even while working through the handoff process, which speaks to the efforts and professionalism of both the HLS and Pfizer teams. Speaker 200:06:38Our new model is built for both efficiency and effectiveness. We are focused on 3 key elements to drive profitable growth. 1, a renewed emphasis on driving new patient starts 2, an increased focus on physician practices with a high number of privately insured patients and 3, providing reimbursement and patient support programs to augment our selling efforts. With our new model, we're covering over 80% of all Vascepa prescribers as well as over 90% of prescribers who have initiated 1 or more new patients within the last 12 months. Despite a considerable reduction in total sales force size, this model still provides coverage of active Vascepa prescribers that's comparable to what we had previously with Pfizer. Speaker 200:07:32Approximately 2 thirds of our sales force effort will be focused on existing prescribers. Here, we want to increase prescribing depth amongst those physicians who are initiating new to brand patient starts. The other one third of selling activity is allocated to targeting those high potential writers who have yet to prescribe. We estimate that bringing primary care in house will result in annual net savings of about $4,000,000 Importantly, we don't believe these savings will come at the expense of growing Vascepa further. We're confident in our new selling model for 5 key reasons. Speaker 200:08:11Number 1 is coverage. We still maintain high level of coverage with existing prescribers and high potential non writers. Number 2 is targeting. We are incorporating new data sources to improve the return on investment of our selling efforts. One example includes leveraging a new data set that captures payer dynamics at the practice level. Speaker 200:08:32This has enabled us to increase focus on the private payer opportunity where most plans have broader patient eligibility criteria, a simpler reimbursement process and a higher value per script. Number 3 is focus. Brand awareness is high in primary care due to Pfizer's previous activities. That said, Vascepa is our only focus on each sales call, whereas the Pfizer primary care reps were responsible for detailing multiple products across different therapeutic areas. Number 4 is ownership. Speaker 200:09:07We are observing synergies in having our reps as a single point of customer contact within a given geography. For example, making connections between specialists and general practitioners that previously would require coordination between the HLS and Pfizer teams can now be handled by a single sales professional. And finally, number 5 is flexibility. Our ability to pivot more quickly on messaging, targeting and other sales tactics is now enhanced. A recent example is an increased focus on the significant cardiovascular death benefit from REDUCE IT, which is a highly differentiating clinical message for Vascepa. Speaker 200:09:47Beyond these important changes to our selling model, we also continue to make progress on reimbursement and patient retention. We gained public access in Alberta in August, which brings our national coverage to more than 90% of Canadian lives covered by public payer plans. It's still early days in Alberta, but we are encouraged by the progress so far, particularly as it relates to recent growth in new patient starts. In Ontario and Quebec, our dedicated field nurses continue to be a resource to physician offices in helping manage the reimbursement process. In offices that utilize these resources, we see higher approval rates and reduced waiting times for new patients. Speaker 200:10:34To improve patient retention, we enhanced our co pay program in May with a particular focus on privately insured patients who are more likely to drop off therapy due to higher co pays. While it is still in the early days of the program, initial results are encouraging in demonstrating a higher level of retention. Improving the retention rate for privately insured patients should also help stabilize the payer mix. So to sum up on Vascepa, we are excited to regain full responsibility for all sales activities. The sales force transition went smoothly, and we have continued to see unit volumes steadily grow in September October. Speaker 200:11:15And we expect Vascepa to deliver a positive brand contribution to adjusted EBITDA for the first time starting in Q4. As a reminder, Vascepa has a long patent runway into the late 2030s, and as such, we believe it will be a profitable growth driver for HLS for many years. Looking now at Clozaril. Our Canadian business continues to deliver encouraging results with Q3 up about 1% year over year in constant currency, while year to date revenue is essentially flat. With a positive start to Q4, we remain on track to stabilize or even modestly grow the Canadian Clozril business this year, driven by our regional strategies in Ontario, Quebec and Western Canada. Speaker 200:12:06In Quebec, Bill 92 limits the ability of prescribers to start new patients on branded Clozaril. Therefore, we recently shifted from a traditional selling approach that focuses on new patient acquisition to a model focused retaining current Clozaril patients. We believe this new approach is working. Since adopting our new model earlier this year in Quebec, Clozaril has seen the lowest decline in net patients in that province since Bill 92 came into effect. In Western Canada, we continue to drive market share expansion and in Ontario, we are leveraging HLS's strong leadership position. Speaker 200:12:47As a result, our performance throughout Canada has more than offset small losses in Quebec. Q3 Clozaril patient growth in Canada was 1.8%, while unit volumes were up about 1% versus prior year. This was driven by patient growth of more than 15% in British Columbia and 3% in Ontario, offsetting patient decline of about 3% in Quebec. Now in contrast to our Canadian Clozaril business, which is flat to last year, the U. S. Speaker 200:13:21Performance is behind plan and we expect U. S. Clozaril net sales will decline about $1,000,000 versus last year. As I've spoken about on previous calls, underlying demand is relatively stable and the sales decline is mainly due to high wholesaler inventory levels at the end of last year. We expected this inventory overhang could be offset through incremental gains in new business as well as through a modest price increase that was taken mid year. Speaker 200:13:51We have made improvements to our existing specialty pharmacy program to help drive business, but an additional goal of expanding our U. S. Pharmacy network will likely happen in 2025 rather than this year. Now moving on to our balance sheet and future capital allocation. While we take steps to grow our product portfolio and improve profitability, we're also strengthening our balance sheet. Speaker 200:14:18During the Q3, we made a significant debt repayment of $14,000,000 using the upfront cash proceeds received from the sale of our ZEMPOZYM royalty interest. This, along with our regular quarterly principal repayment, has lowered our net debt position to $52,400,000 We plan to continue to delever and further strengthen our financial position. We also expect to resume share buybacks in early 2025 as well as more aggressively pursue BD opportunities to expand our product portfolio. As it's a question that often comes up, I'd like to touch briefly development. HLS is highly regarded within Canada for our capabilities and customer relationships within specialty therapeutic areas. Speaker 200:15:08And this positions us well as a potential Canadian licensing partner. As such, we are interested in pursuing assets that are potentially synergistic with our current portfolio and accretive in the near term. Our current BD targeting approach is based on 4 criteria. 1, identify commercial stage assets that are available to license in Canada 2, that are within our therapeutic areas of focus 3, that we believe have considerable sales potential and 4, that won't require significant upfront capital or a large increase in OpEx. In summary, our intent is to bring in assets at a reasonable cost that could significantly grow the top line, while also allowing us to more fully leverage the infrastructure, expertise and capabilities we have built in Canadian specialty markets, specifically within cardiovascular and CNS. Speaker 200:16:04Now that we've made considerable progress in addressing our cost structure and strengthening our balance sheet, adding to the portfolio will be an important lever to accelerate both top line and bottom line growth beyond 2025. Moving on to 2024 full year guidance. We are now guiding to a revenue range of $56,500,000 to $57,200,000 lowered from the previous range of $58,500,000 to $59,700,000 The revised guidance is attributable to year to date U. S. Clozaril sales being behind plan and from the negative foreign exchange impact on the company's Canadian business due to the persistent strength of the U. Speaker 200:16:50S. Dollar relative to the Canadian dollar in 2024. As I stated before, the underlying demand fundamentals for U. S. Clozaril remain sound and the net sales decline is due to what we believe are transient issues. Speaker 200:17:06Sales performance for our Canadian business for both Vascepa and Clozaril is in line with expectations, but reporting results are impacted by the translation to U. S. Dollars. Based on the positive progress in reducing operating costs, we are raising the low end of our 2024 adjusted EBITDA guidance to $16,000,000 to $16,700,000 compared to the previous range of 15.5 $1,000,000 to $16,700,000 We are also reaffirming that Vascepa will make a positive brand contribution to adjusted EBITDA starting in Q4. With our release today, we are also providing a preliminary outlook for next year. Speaker 200:17:50In 2025, we expect that revenue growth from our promoted product portfolio will be in the high single digit percentage range, while growth in consolidated adjusted EBITDA will be in the mid-20s percentage range. We will update our 2025 financial outlook when we release our 2024 year end results in March next year. In closing, we are executing our plan and have made necessary changes throughout this transition year to significantly reduce OpEx and debt levels. We believe this sets up well for 2025 with 2 profitable products generating top line growth along with a stronger balance sheet than we entered 2024 with. This should allow us to resume stock buybacks early next year and pursue portfolio expansion opportunities. Speaker 200:18:40With that, I'll turn it over to John for a closer look at the numbers. John? Speaker 300:18:45Thank you, Craig, and good morning, everyone. Starting with revenue, total revenue for Q3 was $14,100,000 compared to $16,000,000 in Q3 last year. Excluding royalties, revenue from marketed products in Q3 was $13,900,000 up 3% from Q3 2023. Canadian product sales of Vascepa and Plazril in Q3 were up 11% in Canadian dollars. Q3 sales growth in Canada was driven by Vascepa with revenue up 30% in Canadian dollars. Speaker 300:19:21The variance between unit demand growth and net sales growth through Vascepa is due to trends in gross to net pricing. As public access ramps in BC and Alberta following the listings there this year, we expect near term divergence between unit growth and net sales. However, longer term, we expect this to stabilize as public payer growth normalizes. And as Craig discussed, we are also pursuing initiatives to drive patient pardon me, drive private payer patient adoption. U. Speaker 300:19:51S. Closure product sales were down 15% in Q3 and 8% for the year to date period. As Craig touched on, year to date results have been impacted by wholesaler purchasing patterns, including a high level of wholesaler inventory at the start of the year as well as a key downstream customer switching from 1 wholesaler to another, a transition that took place during Q3. The result of this change was lower days on hand of inventory at wholesalers at September 30. This appears to have rebalanced in October. Speaker 300:20:27Royalty revenues were $200,000 in Q3, down from $2,600,000 in Q3 last year. As you know, the royalty term for Emblem, what was the largest royalty in the portfolio came to an end in Q4 last year. In addition, we sold our royalty interest in Zempozyme at the end of Q2 this year. So while prior period royalty includes royalty revenue contributions from multiple royalty interests, Q3 2024 royalty revenue did not include either Emblem or Zempozyme. As Craig mentioned, following the sale of Zempozyme, we used the cash proceeds to make a $14,000,000 principal payment on our term loan in Q3, which will save us approximately $1,500,000 in annual interest expense. Speaker 300:21:17On the expense side, we continued to make progress in Q3 with reducing our cost base while maintaining the growth potential of the business. Q3 operating expenses comprising sales and marketing, G and A and medical regulatory and patient support were down 15%, while promoted product revenue in Canada was up 9%. With the transition of the primary care sales function to HLS completed at the end of August, we generated some related savings in Q3, but we'll see a more substantive decrease in sales and marketing expense in Q4 this year, which will continue going forward. As Craig said earlier, we expect the transition to save us a net amount of approximately $4,000,000 annually or about $1,000,000 per quarter starting in Q4. We recorded other costs in the quarter of approximately $600,000 related to the exiting of the co promotional agreement. Speaker 300:22:15In Q4, we expect another related expense though of a smaller magnitude. Finally, cost of product sales increased in Q3 due to growth of Vascepa year over year. Q3 adjusted EBITDA was $4,100,000 compared to $5,100,000 in Q3 2023. Excluding royalty revenue, adjusted EBITDA for Q3 would have been $3,900,000 compared to $2,500,000 in Q3 last year. This represents a year over year increase of 55%. Speaker 300:22:50This reflects the growth in our promoted product revenue as well as steps we have taken to reduce our cost base. For Q3, the Direct Brand contribution from Clozaril to adjusted EBITDA was $6,800,000 while the Direct Brand contribution from Vascepa to adjusted EBITDA was a loss of 600,000 dollars Year to date, the Direct Brand contribution from Clozaril to adjusted EBITDA was $20,500,000 while the Direct Brand contribution from Vascepa to adjusted EBITDA was a loss of 3,800,000 dollars By comparison for the same year to date period 2023, Vascepa brand contribution was negative $6,900,000 We've seen a 45% improvement. Cash from operations in Q3 was $1,500,000 compared to $5,400,000 in Q3 last year. Cash and cash equivalents were $17,500,000 at quarter end compared to $22,000,000 at December 31, 2023. We continue to delever our balance sheet and made a regular principal repayment on our term loan during Q3 of approximately $1,000,000 in addition to the $14,000,000 debt repayment mentioned earlier. Speaker 300:24:06At the quarter end, the principal balance on the term loan stood at $70,000,000 down significantly from $88,500,000 at the end of 2023. Our net debt at the end of Q3 stood at $52,400,000 dollars In closing, I'm excited to take on the role of permanent CFO this time in the company's evolution. We expect to end the year with a stronger balance sheet, reduced cost base and an outlook for 2 profitable products in 2025. Overall, the improvements we've made in 2024 put us in a financial position to support the potential of our existing products, while providing the optionality to buy back shares and our expand product portfolio. And with that, I'll pass it back to Craig for his closing comments. Speaker 200:24:54Thanks, John. To sum up, we are making progress in executing our plan, continuing to grow our promoted products while significantly reducing operating expenses and paying down debt in 2024. We believe the changes we're making this year will set HLS up for top line growth and increased profitability in 2025 and create greater flexibility for capital allocation in the future. That concludes my prepared remarks. At this point, I'll ask the operator to please provide instructions for asking a question. Speaker 200:25:26Operator? Operator00:25:28Thank you. And ladies and gentlemen, we will now begin the question and answer And your first question comes from the line of George Olyvishov with Klarman Securities. Please go ahead. Speaker 300:26:39Good morning, guys. Thanks for taking our questions and congrats, John, on the appointment. Just a few here on my end. Can you guys talk a little bit about the trends you're seeing when it comes to relative growth in consistent prescribers for Vascepa in each of the 4 key provinces? Speaker 200:27:00Thanks, George, for the question. And since we're also fortunate to have Brian Walsh here with us, our Chief Commercial Officer, maybe I'll see if Brian has some perspectives on the growth in consistent prescribers. And maybe just to start, maybe a definition of what that is, Brian? Speaker 400:27:24Sure. Thanks George. Thanks for the question. Thanks Craig. So consistent prescribers, we look at nationally. Speaker 400:27:34It's defined by prescribers that have written 4 out of the last 5 weeks. We've seen 66% growth versus last year in consistent prescribers. And now approximately 45% of our prescribers within the quarter were consistent prescribers for Vascepa. Yes. Do we Speaker 200:27:53see any differences in terms of regional differences? I think that and I'm not sure if we have that information handy, so we might need to follow-up with you on that, George. Speaker 400:28:01I think the one metric we look at it very closely regionally is more new to brand initiators. So for the quarter, we saw the biggest improvement there in BC as expected with access about 75% increase in new to brand writers in BC for Q3 versus Q3 prior year. Speaker 300:28:22Got it, got it. Understood. Thanks, Brian, and thanks, Greg. Moving on, I guess, also on Vascepa, can you give us a sense of roughly what percentage of new to brand patients today are originating from primary care versus specialty care? Speaker 400:28:40Yes. So it's about 2 thirds from specialty and 1 third from primary care in the most recent quarter. Speaker 300:28:51Okay. Got it. Got it. And just switching gears here a little bit. With respect to the expansion of the specialty pharmacy program for Clozro in the U. Speaker 300:29:02S, what are your plans for that? And what kind of impact are you guys expecting in 2025? Speaker 400:29:11Yes. So the program that we have in place now is it's been with a strong partner that's focused on providing access to branded Clozaril obviously in the U. S. We've seen that program double in size this year versus last year, now representing about 10% of our units for the U. S. Speaker 400:29:32So we expect to be able to continue to grow that program. That program has broadly national reach, but we have some pockets, regional pockets of opportunity that we aim to fill in with other mental health specialty pharmacies in the U. S. In 2025. So I think we can expect to see that level of growth within the program, which is offsetting any decline in base business in the rest of the country. Speaker 300:30:00Understood. Understood. That's it for me. Thank you, guys. Thanks, George. Operator00:30:08Thank you. And there are no further questions at this time. I would like to turn it back to Craig Millian for closing remarks. Speaker 200:30:14Great. Thank you. And thanks for participating on today's call. And we look forward to continuing to report on our progress in the coming quarters and speaking with you all again soon. Goodbye. Speaker 200:30:25Have a great day. Operator00:30:28Thank you. Ladies and gentlemen, this concludes today's conference call. Thank you all for participating. You may now disconnect.Read morePowered by